News and Events

Pegpesen(Pegsomatropin Injection) has approved for clinical trial of its new indication

Approval Granted for Amoytop Biotech's Pegpesen®, a Next-Gen Long-Acting Growth Hormone

On May 29, Amoytop Biotech's independently developed Class 1 new drug, Inpegsomatropin Injection(trade name: Pegpesen®), the world's first Y-shaped 40-kDa PEGylated long-acting growth hormone, officially received market approval from the National Medical Products Administration (NMPA). This drug is

A New Journey Begins: First National Batch Shipment of Pegpesen® (Pegsomatropin Injection)

Xinhuanet: Launch Ceremony of Pediatric Innovative Drugs and the "Little Bamboo Shoot" Project Held in Beijing